CLAIMS

5

25

- 1. Combined pharmaceutical preparation containing G-CSF and PIGF as the active substances, for use in the mobilization of blood stem cells in a patient or subject in need thereof.
- 2. Combined preparation according to claim 1, wherein G-CSF and PIGF are simultaneously or separately administered to said patient or subject.
- 3. Combined preparation according to claims 1-2, for parenteral administration.
- 10 4. Combined preparation according to claims 1-3, containing recombinant hG-CSF and rhPlGF.
 - 5. Combined preparation according to claims 1-4, containing from 1 to $150 \mu g/kg$ G-CSF and from 10 to 300 $\mu g/kg$ PlGF.
- 6. Use of a combination of G-CSF and PIGF in the manufacture of a pharmaceutical composition for the treatment of states, conditions or diseases that require the mobilization of blood stem cells.
 - 7. Use according to claim 6, in the manufacture of a parenteral composition.
- 8. Use according to claim 6 of a combination of recombinant hG-CSF and rhPlGF.
 - 9. Use according to claim 6, wherein said states, conditions or diseases include organ or cell transplantation and tumor chemo-radiotherapy, in particular autologous or allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma (NHL), relapsed Hodgkin lymphoma (HL), multiple myeloma, or the recovery phase following myelosuppressive chemotherapy.
 - 10. Use according to claim 6, wherein the pharmaceutical composition provides a daily amount of 10 μ g/kg G-CSF and of 130 μ g/kg PIGF.